Dr. Holger Hofmeister advises corporate clients and private equity firms in connection with acquisitions, divestitures, public takeovers, joint ventures, and other M&A and corporate matters, including capital markets-related issues. In addition, he advises on corporate governance-related matters and corporate restructurings.

Bio

Dr. Hofmeister was named in WirtschaftsWoche as one of the best corporate lawyers in Germany. In addition, he has been named by both Handelsblatt and WirtschaftsWoche as one of Germany’s top M&A advisors. He also is listed as recommended lawyer in JUVE.

  • Airbnb, Inc. in its acquisition of Germany-based fewoVista S.L. & Co. KG and Vacaleo GmbH;
  • Apax Partners in connection with:
    • its proposed US$8.5 billion bid for ISS/AS, a facilities management provider, from Goldman Sachs Capital Partners and EQT Partners AB; and
    • the US$420 million sale of Versatel AG, a provider of telecommunications and information technology services, to Kohlberg Kravis Roberts & Co., a private equity firm;
  • Braskem S.A. in its US$323 million acquisition of the polypropylene business from The Dow Chemical Company;
  • Daimler AG in connection with various matters including:
    • the carve-out and disposals of Daimler dealerships throughout Germany, Belgium and Luxembourg;
    • projects relating to the cooperation with Renault-Nissan-Alliance;
    • various real estate disposals;
    • the sale of its subsidiary Russ & Janot GmbH to Lei Shing Hong Limited, a Hong Kong-based company engaged in automobile and heavy machinery distribution;
    • the sale of its subsidiary Taunus-Auto-Verkaufs GmbH to KBM Motorfahrzeuge GmbH & Co. KG, a German automobile and heavy machinery distributor; and
    • the divestiture of its worldwide Chrysler distribution business;
  • Dürr AG, a major German industrial machinery group, in connection with:
    • several M&A transactions including the acquisition of iTAC Software AG; and
    • the formation of the joint venture ADAMOS (ADAptive Manufacturing Open Solutions) with Software AG, an enterprise software company; DMG Mori, a machine tool manufacturer; optical group Zeiss; and ASM PT, a tool manufacturer of circuit boards;
  • Fresenius SE & Co. KGaA, a health care company in Germany, in the sale of Fresenius Biotech GmbH to the Fuhrer family, owners of Neopharm Ltd., a pharmaceutical company;
  • Hillenbrand, Inc., a holding company for a funeral products manufacturer and an industrial equipment supplier, in its:
    • definitive agreement to acquire Abel GmbH & Co. KG, a manufacturer of inter alia diaphragm pumps and certain of its affiliates from Roper Technologies, Inc., a diversified technology company, for €95 million in cash; and
    • US$530 million acquisition of Coperion GmbH, a manufacturer of industrial machinery and plants, from Deutsche Beteiligungs AG, a private equity firm;
  • Hamburg Commercial Bank (f/k/a HSH Nordbank) in connection with its privatization and related matters, including the sale of a loan portfolio;
  • IAC/InterActive Corp in its acquisition of a majority shareholding in MyHammer Holding AG from Holtzbrinck Digital GmbH and the subsequent voluntary takeover;
  • KAP-Beteiligungs-Aktiengesellschaft in its public takeover by a subsidiary of The Carlyle Group and in connection with several M&A transactions;
  • Koenigsegg Group in the proposed acquisition of Saab, the Swedish auto manufacturer, from General Motors;
  • Konecranes Plc in its US$1.5 billion acquisition of Terex Corporation’s material handling and port solutions business segment;
  • LANXESS AG, a global specialty chemicals company, in its US$2.5 billion all-cash acquisition of Chemtura Corporation;
  • Merck KGaA, a biotechnology and pharmaceutical company, a distributor of laboratory products, and a manufacturer of specialty chemicals, food additives and cosmetics, in connection with:
    • its €13.8 billion all-cash acquisition of Sigma-Aldrich Corporation and in the divestiture of certain business of Merck/Sigma-Aldrich to obtain antitrust clearance for such acquisition; and
    • the US$6.7 billion sale of its worldwide generic drugs business to Mylan Laboratories, Inc. Prior to sale, the business underwent a significant reorganization with a number of related carve-out transactions to separate the generics business from the remaining Merck group;
  • Odewald & Compagnie, a private equity firm, in its acquisition of Oberberg Kliniken, an operator of mental health clinics;
  • Quadriga Capital in connection with various M&A transactions, including the sale (together with Barclays Private Equity) of Jack Wolfskin GmbH, a manufacturer and retailer of sportswear and apparel, to The Blackstone Group, L.P.;
  • The SCP Group in its acquisition of Real GmbH from METRO AG;
  • Süd-Chemie AG in the formation of a US$300 million joint venture with Ashland Inc. to merge their foundry chemicals businesses under the name of ASK Chemicals GmbH;
  • Telegraaf Media Groep N.V. in the sale of its interest in SBS Broadcasting and its option to purchase a minority stake in ProSiebenSat.1 Media AG;
  • TPV Technology Limited in the proposed acquisition of a 70 percent interest in a joint venture, which will own and control the entire television business of Koninklijke Philips Electronics N.V. in Europe and certain South American countries;
  • Vue Entertainment Ltd. in its acquisition of CinemaxX AG from Dr. Herbert Kloiber, Dr. Kloiber Vermögensverwaltungsgesellschaft mbH & Co. Beteiligungs KG and other shareholders; and
  • WABCO Holdings Inc. in its US$7 billion acquisition by ZF Friedrichshafen AG.

Credentials

Education

  • Dr. Jur., University of Regensburg, 1999
  • Second State Exam, Appellate Court of Duesseldorf, 2001
  • First State Exam, University of Regensburg, 1998

Admissions

  • Frankfurt am Main

Holger Hofmeister